OS Therapies Inc (NYSE:OSTX) Major Shareholder Shalom Auerbach Sells 100,000 Shares

OS Therapies Inc (NYSE:OSTX) major shareholder Shalom Auerbach sold 100,000 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $2.84, for a total transaction of $284,000.00. Following the completion of the sale, the insider now directly owns 2,431,211 shares in the company, valued at approximately $6,904,639.24. The trade was a 3.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shalom Auerbach also recently made the following trade(s):

• On Wednesday, January 15th, Shalom Auerbach sold 16,720 shares of OS Therapies stock. The shares were sold at an average price of $6.74, for a total transaction of $112,692.80.

OS Therapies Trading Down 5.6 %

Shares of OS Therapies stock opened at $1.86 on Thursday. The firm has a 50-day simple moving average of $3.36 and a two-hundred day simple moving average of $3.15. OS Therapies Inc has a fifty-two week low of $1.58 and a fifty-two week high of $7.00.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $20.00 price target on shares of OS Therapies in a report on Thursday, January 30th. Maxim Group upped their price target on shares of OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, January 16th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC acquired a new position in OS Therapies Inc (NYSE:OSTX) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.